Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091177 | 0.92 | ALDH1A1 (0.44) | AGTR1ALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL443941 | 0.78 | ALDH1A1 (0.42) | ALDH1A1LMNACA1CA2KMT2A | |
| SCHEMBL448304 | 0.73 | ALDH1A1 (0.43) | ALDH1A1LMNACA1CA2KMT2A | |
| SCHEMBL5099364 | 0.73 | ADCY6 (0.41) | ALDH1A1LMNAKMT2ANR1H4 | |
| SCHEMBL446694 | 0.72 | ADCY6 (0.42) | ALDH1A1LMNAKMT2ANR1H4 | |
| SCHEMBL443391 | 0.72 | ALDH1A1 (0.46) | ALDH1A1LMNAKMT2ANR1H4TSHR | |
| SCHEMBL4638349 | 0.71 | AGTR1 (0.47) | AGTR1ALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL9710078 | 0.71 | AGTR1 (0.43) | AGTR1KMT2APOLBTSHR | |
| SCHEMBL3883657 | 0.70 | AGTR1 (0.47) | AGTR1ALDH1A1KMT2APOLBRAB9A | |
| SCHEMBL9710053 | 0.70 | AGTR1 (0.46) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | AGTR1 41/4885ALDH1A1 53/4885LMNA 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.